8-K Announcements
6Material company update
Mar 26, 2026·SEC
Material company update
Mar 25, 2026·SEC
Material company update
Nov 10, 2025·SEC
Nkarta, Inc.(NKTX)Earnings, Financials & Key Ratios
NKTX•NASDAQ
$3.32
$235M mkt cap·Price updated May 6, 2026
AboutNkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.Show more
- Revenue$0
- EBITDA-$119M+5.4%
- Net Income-$109M+7.4%
- EPS (Diluted)-1.60+33.3%
- ROE-31.94%+12.3%
- ROIC-24.31%+7.9%
- Debt/Equity0.20-39.1%
NKTX Key Insights
Nkarta, Inc. (NKTX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 80 (top 20%)
- ✓Trading at only 0.6x book value
✗Weaknesses
- ✗Shares diluted 38.5% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
NKTX Price & Volume
Nkarta, Inc. (NKTX) stock price & volume — 10-year historical chart
Loading chart...
NKTX Growth Metrics
Nkarta, Inc. (NKTX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM7.23%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM26.6%
Return on Capital
10 Years-36.04%
5 Years-30.78%
3 Years-32.22%
Last Year-30.6%
NKTX Recent Earnings
Nkarta, Inc. (NKTX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)
Q2 2026Latest
Mar 25, 2026EPS
$0.37
Est $0.32
-15.6%
Revenue
—
Q4 2025
Nov 10, 2025EPS
$0.29
Est $0.32
+9.4%
Revenue
—
Q3 2025
Aug 12, 2025EPS
$0.31
Est $0.37
+16.2%
Revenue
—
Q2 2025
May 14, 2025EPS
$0.43
Est $0.44
+2.3%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 25, 2026 | $0.37vs $0.32-15.6% | — |
| Q4 2025 | Nov 10, 2025 | $0.29vs $0.32+9.4% | — |
| Q3 2025 | Aug 12, 2025 | $0.31vs $0.37+16.2% | — |
| Q2 2025 | May 14, 2025 | $0.43vs $0.44+2.3% | — |
Based on last 12 quarters of dataView full earnings history →
NKTX Peer Comparison
Nkarta, Inc. (NKTX) competitors in Cell and Gene Therapy Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 FATE | 264.17M | 2.29 | -1.99 | -51.24% | -20.51% | -65.79% | 0.38 | |
 CELC | 6.03B | 139.44 | -49.27 | -179% | 0.85 | |||
 STTK | 421.85M | 6.68 | -4.48 | 245.26% | -54.9% | -58.87% | 0.04 | |
 IOVA | 1.68B | 4.09 | -3.75 | 60.6% | -148.38% | -55.97% | 0.07 | |
 TCRX | 162.33M | 1.25 | -1.25 | 266.65% | -12.57% | -79.36% | 0.76 | |
 CRSP | 5.17B | 55.08 | -8.51 | -89.97% | -13.29% | -25.49% | 0.11 | |
 NTLA | 1.61B | 13.85 | -3.64 | -100% | -61.47% | 0.14 | ||
 BEAM | 3.32B | 32.33 | -39.92 | 120.01% | -57.24% | -7.31% | 0.24 |
Compare NKTX vs Peers
Nkarta, Inc. (NKTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
NKTX Income Statement
Nkarta, Inc. (NKTX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 6.55M | 115.39K | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | -98.24% | -100% | - | - | - | - | - |
| Cost of Goods Sold | 4.25M | 17.22K | 0 | 0 | 0 | 5.87M | 0 | 0 |
| COGS % of Revenue | 64.92% | 14.92% | - | - | - | - | - | - |
| Gross Profit | 2.3M▲ 0% | 98.17K▼ 95.7% | 0▼ 100.0% | 0▲ 0% | 0▲ 0% | -5.87M▲ 0% | 0▲ 100.0% | 0▲ 0% |
| Gross Margin % | 35.08% | 85.08% | - | - | - | - | - | - |
| Gross Profit Growth % | - | -95.73% | -100% | - | - | - | 100% | - |
| Operating Expenses | 6.91M | 22.46M | 51.51M | 86.43M | 118.95M | 125.78M | 128.19M | 121.96M |
| OpEx % of Revenue | 105.44% | 19468.66% | - | - | - | - | - | - |
| Selling, General & Admin | 2.65M | 5.25M | 15.29M | 23.02M | 28.06M | 34.88M | 31.45M | 28.58M |
| SG&A % of Revenue | 40.52% | 4547.35% | - | - | - | - | - | - |
| Research & Development | 4.25M | 17.22M | 36.22M | 63.41M | 90.9M | 90.9M | 96.74M | 88.28M |
| R&D % of Revenue | 64.92% | 14921.31% | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1000K |
| Operating Income | -356.45K▲ 0% | -22.35M▼ 6169.8% | -51.51M▼ 130.5% | -86.43M▼ 67.8% | -118.95M▼ 37.6% | -131.65M▼ 10.7% | -128.19M▲ 2.6% | -121.96M▲ 0% |
| Operating Margin % | -5.44% | -19368.66% | - | - | - | - | - | - |
| Operating Income Growth % | - | -6169.77% | -130.48% | -67.8% | -37.63% | -10.67% | 2.63% | - |
| EBITDA | -173.24K | -21.8M | -50.72M | -84.67M | -116.32M | -125.78M | -119.04M | -112.73M |
| EBITDA Margin % | -2.64% | -18889.15% | - | - | - | - | - | - |
| EBITDA Growth % | - | -12481.32% | -132.72% | -66.94% | -37.37% | -8.14% | 5.36% | 5.54% |
| D&A (Non-Cash Add-back) | 183.21K | 553.28K | 786K | 1.76M | 2.64M | 5.87M | 9.15M | 9.22M |
| EBIT | -274.5K | -20.6M | -51.51M | -86.43M | -118.95M | -126.35M | -128.19M | -111.29M |
| Net Interest Income | 81.95K | -169K | 313K | 370K | 0 | 14.11M | 19.32M | 17.09M |
| Interest Income | 81.95K | 304K | 313K | 370K | 5.59M | 14.11M | 19.32M | 17.09M |
| Interest Expense | 0 | 473K | 0 | 0 | 5.59M | 0 | 0 | 0 |
| Other Income/Expense | 81.95K | 1.27M | -39.85M | 354K | 5.12M | 14.15M | 19.4M | 19.35M |
| Pretax Income | -274.5K▲ 0% | -21.08M▼ 7577.8% | -91.36M▼ 333.5% | -86.08M▲ 5.8% | -113.84M▼ 32.3% | -117.5M▼ 3.2% | -108.79M▲ 7.4% | -102.61M▲ 0% |
| Pretax Margin % | -4.19% | -18265.66% | - | - | - | - | - | - |
| Income Tax | 0 | 1.81M | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | -8.58% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -274.5K▲ 0% | -21.08M▼ 7577.8% | -91.36M▼ 333.5% | -86.08M▲ 5.8% | -113.84M▼ 32.3% | -117.5M▼ 3.2% | -108.79M▲ 7.4% | -102.61M▲ 0% |
| Net Margin % | -4.19% | -18265.66% | - | - | - | - | - | - |
| Net Income Growth % | - | -7577.82% | -333.49% | 5.79% | -32.25% | -3.22% | 7.41% | 7.23% |
| Net Income (Continuing) | -274.5K | -21.08M | -91.36M | -86.08M | -113.84M | -117.5M | -108.79M | -102.61M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.01▲ 0% | -2.55▼ 46263.6% | -1.59▲ 37.6% | -2.62▼ 64.8% | -2.61▲ 0.4% | -2.40▲ 8.0% | -1.60▲ 33.3% | -1.39▲ 0% |
| EPS Growth % | - | - | 37.65% | -64.78% | 0.38% | 8.05% | 33.33% | 26.6% |
| EPS (Basic) | -0.01 | -2.55 | -1.59 | -2.62 | -2.61 | -2.40 | -1.60 | - |
| Diluted Shares Outstanding | 50.27M | 8.98M | 31.8M | 32.86M | 43.63M | 49.01M | 67.87M | 74.02M |
| Basic Shares Outstanding | 50.27M | 8.98M | 31.8M | 32.86M | 43.63M | 49.01M | 67.87M | 74.02M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
NKTX Balance Sheet
Nkarta, Inc. (NKTX) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 8.23M | 37.47M | 318.83M | 245.78M | 360.69M | 253.07M | 273.34M | 289.27M |
| Cash & Short-Term Investments | 7.87M | 36.99M | 314.91M | 238.09M | 352.14M | 248.19M | 267.35M | 282.33M |
| Cash Only | 7.87M | 20.61M | 96.69M | 60.82M | 37.49M | 31.04M | 27.87M | 60.11M |
| Short-Term Investments | 0 | 16.38M | 218.22M | 177.27M | 314.65M | 217.15M | 239.48M | 222.22M |
| Accounts Receivable | 150K | 0 | 0 | 0 | 1.3M | 200K | 200K | 0 |
| Days Sales Outstanding | 8.36 | - | - | - | - | - | - | - |
| Inventory | 117.29K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | 10.07 | - | - | - | - | - | - | - |
| Other Current Assets | 94.42K | 66.51K | 1.34M | 3.15M | 1.63M | 1.42M | 2.54M | 6.94M |
| Total Non-Current Assets | 1.38M | 10.95M | 18.82M | 28.12M | 112.25M | 125.81M | 227.87M | 137.96M |
| Property, Plant & Equipment | 1.29M | 10.22M | 17.86M | 24.53M | 107.66M | 119.28M | 110.67M | 101.98M |
| Fixed Asset Turnover | 5.09x | 0.01x | - | - | - | - | - | 0.00x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 89.81K | 268.54K | 0 | 0 | 2.74M | 2.74M | 110.39M | 267.07M |
| Other Non-Current Assets | 0 | 455.08K | 960K | 3.59M | 1.85M | 3.8M | 6.8M | 23.33M |
| Total Assets | 9.61M▲ 0% | 48.41M▲ 404.0% | 337.65M▲ 597.5% | 273.9M▼ 18.9% | 472.94M▲ 72.7% | 378.88M▼ 19.9% | 501.2M▲ 32.3% | 427.24M▲ 0% |
| Asset Turnover | 0.68x | 0.00x | - | - | - | - | - | 0.00x |
| Asset Growth % | - | 404.01% | 597.45% | -18.88% | 72.67% | -19.89% | 32.28% | -24.93% |
| Total Current Liabilities | 2.08M | 8.21M | 8.83M | 12.94M | 22.05M | 23.33M | 18.92M | 18.99M |
| Accounts Payable | 367.17K | 1.88M | 1.18M | 1.11M | 1.76M | 3.67M | 638K | 1.44M |
| Days Payables Outstanding | 31.52 | 39.9K | - | - | - | 227.93 | - | - |
| Short-Term Debt | 0 | 0 | 0 | 0 | 4.25M | 0 | 0 | 6.37M |
| Deferred Revenue (Current) | 0 | 2.7M | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 408.44K | -857.45K | 117K | 96K | 9.35M | 6.72M | 254K | 11.18M |
| Current Ratio | 3.96x | 4.56x | 36.10x | 18.99x | 16.36x | 10.85x | 14.45x | 14.45x |
| Quick Ratio | 3.91x | 4.56x | 36.10x | 18.99x | 16.36x | 10.85x | 14.45x | 14.45x |
| Cash Conversion Cycle | -13.09 | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 12.92M | 65.68M | 7.6M | 9.99M | 78.69M | 82.27M | 74.31M | 70.35M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 70.26M |
| Capital Lease Obligations | 0 | 5.78M | 7.52M | 9.97M | 78.69M | 82.27M | 74.22M | 218.81M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 12.92M | 59.9M | 82K | 18K | 0 | 0 | 87K | 348K |
| Total Liabilities | 15M | 73.89M | 16.43M | 22.94M | 100.73M | 105.6M | 93.23M | 89.34M |
| Total Debt | 12.71M | 7.3M | 8.92M | 12.46M | 82.93M | 88.34M | 80.27M | 76.63M |
| Net Debt | 4.84M | -13.31M | -87.77M | -48.36M | 45.44M | 57.3M | 52.4M | 16.52M |
| Debt / Equity | - | - | 0.03x | 0.05x | 0.22x | 0.32x | 0.20x | 0.20x |
| Debt / EBITDA | - | - | - | - | - | - | - | -0.68x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | -0.15x |
| Interest Coverage | - | -47.25x | - | - | -21.29x | - | - | - |
| Total Equity | -5.4M▲ 0% | -25.48M▼ 372.2% | 321.22M▲ 1360.6% | 250.97M▼ 21.9% | 372.21M▲ 48.3% | 273.29M▼ 26.6% | 407.98M▲ 49.3% | 337.9M▲ 0% |
| Equity Growth % | - | -372.25% | 1360.55% | -21.87% | 48.31% | -26.58% | 49.29% | -13.39% |
| Book Value per Share | -0.11 | -2.84 | 10.10 | 7.64 | 8.53 | 5.58 | 6.01 | 4.56 |
| Total Shareholders' Equity | -5.4M | -25.48M | 321.22M | 250.97M | 372.21M | 273.29M | 407.98M | 337.9M |
| Common Stock | 123 | 160 | 3K | 3K | 5K | 5K | 7K | 7K |
| Retained Earnings | -5.58M | -26.66M | -118.02M | -204.1M | -317.93M | -435.43M | -544.22M | -620.9M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -244.75K | -2.14K | 3K | -150K | -679K | 8K | 674K | 536K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
NKTX Cash Flow Statement
Nkarta, Inc. (NKTX) cash flow — operating, investing & free cash flow history
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -5.18M | -18.37M | -43.51M | -67.93M | -57M | -86.16M | -99.7M | -99.7M |
| Operating CF Margin % | -79.14% | -15918.01% | - | - | - | - | - | - |
| Operating CF Growth % | - | -254.31% | -136.87% | -56.13% | 16.09% | -51.16% | -15.71% | 28.35% |
| Net Income | -274.5K | -21.08M | -91.36M | -86.08M | -113.84M | -117.5M | -108.79M | -102.61M |
| Depreciation & Amortization | 183.21K | 401K | 786K | 1.76M | 2.64M | 5.87M | 2.24M | 8.02M |
| Stock-Based Compensation | 182.51K | 947K | 6.75M | 14.46M | 16.86M | 17.2M | 16.73M | 10.55M |
| Deferred Taxes | 0 | 0 | 738K | 3.24M | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 548.94K | -818K | 40.41M | 337K | 3.61M | -2.65M | 2.29M | -1.72M |
| Working Capital Changes | -5.28M | 2.18M | -828K | -1.64M | 33.74M | 10.93M | -12.16M | -6.05M |
| Change in Receivables | -14.82K | -463.26K | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 689.71K | 2.64M | 2.82M | 2.79M | 2.76M | 4.22M | -4.47M | -2.52M |
| Cash from Investing | -757.88K | -18.3M | -210.08M | 32.53M | -184.69M | 79.02M | -129.56M | 94.7M |
| Capital Expenditures | -757.88K | -1.93M | -7.51M | -5.03M | -47.11M | -28.15M | -4.41M | -1.75M |
| CapEx % of Revenue | 11.57% | 1670.93% | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 202.57K | -37.56K | 137.58K | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | -202.57K | 37.56K | -137.58K | 0 | 0 | 0 |
| Cash from Financing | 87.49K | 49.58M | 329.82M | 1.2M | 219.01M | 691K | 226.08M | 261K |
| Debt Issued (Net) | 0 | 49.53M | 64.32M | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 0 | 1000K | 1000K | 1000K | 1000K | 691K | 1000K | 77K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 87.49K | -43.5M | -63.92M | 0 | 1.84M | 0 | 1.01M | 184K |
| Net Change in Cash | -5.85M▲ 0% | 12.92M▲ 320.7% | 76.23M▲ 490.1% | -34.19M▼ 144.9% | -22.68M▲ 33.7% | -6.45M▲ 71.5% | -3.17M▲ 50.9% | 3.15M▲ 0% |
| Free Cash Flow | -5.94M▲ 0% | -20.3M▼ 241.6% | -51.02M▼ 151.4% | -72.95M▼ 43.0% | -104.11M▼ 42.7% | -114.31M▼ 9.8% | -104.11M▲ 8.9% | -93.55M▲ 0% |
| FCF Margin % | -90.71% | -17588.94% | - | - | - | - | - | - |
| FCF Growth % | - | -241.56% | -151.38% | -43% | -42.71% | -9.79% | 8.93% | 13.71% |
| FCF per Share | -0.12 | -2.26 | -1.60 | -2.22 | -2.39 | -2.33 | -1.53 | -1.53 |
| FCF Conversion (FCF/Net Income) | 18.88x | 0.87x | 0.48x | 0.79x | 0.50x | 0.73x | 0.92x | 0.91x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
NKTX Key Ratios
Nkarta, Inc. (NKTX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | -61.79% | -30.09% | -36.53% | -36.41% | -31.94% | -30.37% |
| Return on Invested Capital (ROIC) | - | -39.69% | -29.73% | -28.77% | -26.39% | -24.31% | -24.31% |
| Gross Margin | 85.08% | - | - | - | - | - | - |
| Net Margin | -18265.66% | - | - | - | - | - | - |
| Debt / Equity | - | 0.03x | 0.05x | 0.22x | 0.32x | 0.20x | 0.20x |
| Interest Coverage | -47.25x | - | - | -21.29x | - | - | - |
| FCF Conversion | 0.87x | 0.48x | 0.79x | 0.50x | 0.73x | 0.92x | 0.91x |
| Revenue Growth | -98.24% | -100% | - | - | - | - | - |
NKTX SEC Filings & Documents
Nkarta, Inc. (NKTX) SEC filings — annual & quarterly reports (10-K, 10-Q)
NKTX Frequently Asked Questions
Nkarta, Inc. (NKTX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Nkarta, Inc. (NKTX) grew revenue by 0.0% over the past year. Growth has been modest.
Nkarta, Inc. (NKTX) reported a net loss of $102.6M for fiscal year 2024.
Dividend & Returns
Nkarta, Inc. (NKTX) has a return on equity (ROE) of -31.9%. Negative ROE indicates the company is unprofitable.
Nkarta, Inc. (NKTX) had negative free cash flow of $93.6M in fiscal year 2024, likely due to heavy capital investments.
Explore More NKTX
Nkarta, Inc. (NKTX) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates